Mesoblast (MESO) EPS (Weighted Average and Diluted) (2017)
Mesoblast recorded quarterly EPS (Weighted Average and Diluted) of $87.84 in Q4 2017.
Mesoblast's EPS (Weighted Average and Diluted) history runs 1 years deep, the most recent figure standing at $87.84 for Q4 2017.
- In Q4 2017, EPS (Weighted Average and Diluted) changed N/A year-over-year to $87.84; the TTM figure through Dec 2017 stood at $87.84 (changed N/A YoY), while the FY2025 annual figure was -$0.08, up 5.05% from the prior year.
- EPS (Weighted Average and Diluted) came in at $87.84 for Q4 2017 at Mesoblast.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $87.84 in Q4 2017 to a low of $87.84 in Q4 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Mesoblast | 23.40 Bn | 23.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 87.84 |